Connor Iapoce

In older adults with atrial fibrillation, rivaroxaban was associated with a significantly increased risk of major ischemic or hemorrhagic events compared to apixaban.

Data show Asian, Black, and Hispanic patients and those with lower income were less likely to receive treatment with GLP-1 RAs.

Data show In 16 of 17 ophthalmic condition categories, North American Native individuals had significantly different claim rates from non-Hispanic White individuals.

Dr. Shapiro discusses the implantable VC-02 device success in producing C-peptide in patients with type 1 diabetes and what is coming next.

A high-potential drug for type 1 diabetes may not have received regulation this year, but it sparked vital conversation among experts.

Patients in a racial and ethnic minority group were less likely to state they were treated with respect by their clinician compared with non-Hispanic White patients (AOR, 0.77).

Engagement had positive associations with higher comfort with technology, visual acuity, nAMD diagnosis, and the number of intravitreal injections.

Dr. Jellinger discusses the lipid section of the DCRM guidelines, the role of combination therapies in lowering LDL and what is coming next for the field of diabetes in 2022.

Data show the proportion of infants with influenza aged <6 months ranged from 1.0 – 2.6% among all infant hospitalizations in the 2019 influenza season.

The TPV system expands transcatheter therapy options for patients with congenital heart valve disease.

In a Dutch population, the prevalence of MMD increased with older age, lower spherical equivalent of refractive error, and higher axial length.

Cardiologists have utilized new technologies during the COVID-19 pandemic.

Topical pimecrolimus 1% treatment had unsatisfactory results, while combination microneedling and topical pimecrolimus treatment showed a favorable outcome.

Data show a total absence of influenza-related hospitalization and mortality during the 2020 - 2021 influenza season in Canada.

Data show the weighted influenza vaccination rate among pregnant women was 54.5%, with one third not having a usual source of care.

Data show patients with sickle cell disease identified by distinct cognitive profile should have neurorehabilitation tailored to each unique profile.

After 2 months of voxelotor treatment, all patients with sickle cell anemia perceived global improvement, but peak VO2 did not change in 8 of 9 patients.

Data show most patients (60.3%) with sickle cell disease achieved a Hb increase of >1 g/dL during the follow-up period.

Data show the majority of patients who initiated crizanlizumab remained on therapy, while a third of patients saw barriers including insurance coverage.

Data from the ADQoC Initiative show that patients with AD are often misdiagnosed or the severity of their disease was undertreated.

Data show 12 of 25 strokes (48%) in a cohort of children did not met the definition of typical stroke related to sickle cell cerebral vasculopathy.

Data show the average maximum cortical capillary RBC velocity is significantly greater in sickle cell mice compared to controls.

New data from the CDC highlights the need to mitigate the potential severity of the influenza season, particularly with COVID-19's substantial impact on care systems.

The cumulative probability of death was 26% at day 7 and increased to 53% at day 21.

The first approval for the novel device was met with acclaim in the field this year. Now, specialists want to see how their colleagues will implement it.

The meta-analysis showed a mean improvement of 15.7 ETDRS letters and central retinal thickness of 269.7 μm at 12 months.

Fish oil intervention and DASH diet show no statistically significant effect on glycemic control and adiposity.

Data show the relative expression of SORT1 gene was upregulated by 4.438 fold in patients with CAD, compared to control.

Dr. Zeitler highlights the long-term microvascular risk complications observed in T2D patients in the TODAY2 observational study.

Data show all 7 studies using relative risk found an association between metabolic syndrome and the development of PAD, but one study (RR: 1.31).